EMA Authorised: Mepsevii (vestronidase alfa) — Ultragenyx Germany GmbH

View source ↗

Summary

The European Medicines Agency authorised Mepsevii (vestronidase alfa) from Ultragenyx Germany GmbH for mucopolysaccharidosis VII in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Vii

Drugs mentioned

• Mepsevii (vestronidase alfa)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis VII. MAH: Ultragenyx Germany GmbH. Decision date: 26/06/2024. Orphan medicine